[New - In The Fed’s Inflation Fight, Biotech May Be The First Casualty](https://wbbsec.com/opinions-and-features/)
[New - In The Fed’s Inflation Fight, Biotech May Be The First Casualty](https://wbbsec.com/opinions-and-features/)
powered by bulletin
In: Press Releases

Executive Teams of Emerging Biotech Companies to Present to Investor Community

For Immediate Release

April 4, 2019

SAN DIEGO, CA – WBB Securities is a sponsor of this year’s Future Leader’s conference. The Newsmakers conference is hosted by BioCentury and will take place at the Millennium Broadway Hotel and Conference Center in New York City on Friday, April 12, 2019.

BioCentury’s Future Leaders conference allows emerging biotechnology companies to help identify investment and partnering prospects. The objective of the Future Leaders conference is to provide emerging pharmaceutical executives, investment funds, and venture capitalists a venue to connect with investor-validated, milestone-rich private and public companies in key therapeutic areas for potential investment and partnership opportunities.

More than 500 delegates are expected to congregate at this year’s Future Leaders conference, representing top financial institutions, pharmaceutical business development executives, and high net worth investors active in the sector. Last year’s Future Leaders audience controlled more than $650 billion in equity assets. Future Leaders in the Biotech Industry is recognized as the industry’s key venue for companies to take their story to Wall Street each spring.

About WBB Securities

WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients.

The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. Our investment bank has participated in over 120 transactions leading to $4 billion placed. Whether raising capital or executing strategic transactions, our banking team is equipped to meet your financial needs and is comprised of some of the most knowledgeable people working in the life sciences domain.

About BioCentury

Since 1993, BioCentury Publications, Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures. BioCentury’s Editorial and Research staff is comprised of industry-recognized business and science editors and writers. The Company’s management team includes executives with backgrounds in international business, publishing, finance, and the biotech and pharmaceutical industries.